Weitzel and Blazer win ASHG Arno Motulsky-Barton Childs Award

City of Hope’s Jeffrey N. Weitzel and Kathleen Blazer are the 2019 recipients of the American Society of Human Genetics’ Arno Motulsky-Barton Childs Award for Excellence in Human Genetics Education.

Weitzel is Chief of the Division of Clinical Cancer Genomics and the Cancer Screening and Prevention Program at City of Hope. Blazer directs City of Hope’s Cancer Genomics Education Program.

This award recognizes individuals for contributions of exceptional quality and importance to human genetics education internationally. Awardees have had long-standing involvement in genetics education, producing diverse contributions of substantive influence on individuals and/or organizations.

Weitzel and Blazer will receive the award, including a plaque and monetary prize, during ASHG’s 69th Annual Meeting Oct. 15 in Houston.

Weitzel and Blazer have worked together for more than 20 years to provide innovative and impactful cancer genomics education to clinicians and researchers from diverse training backgrounds and practice settings across the United States and internationally. Their NCI-funded CGEP initiatives have ranged from educating primary care physicians for referral-level competence, to preparing master’s and doctoral clinicians for leadership in translational cancer genomics research.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.

January 31, 2025

Vol.51 No.04

By Paul Goldberg

Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services.

January 31, 2025

Vol.51 No.04

By Claire Marie Porter

Guest Editorial

Our challenge: To find zen in chaos

This column is a love letter of sorts to our field, a recognition of all that we have accomplished and an acknowledgement that we need to find a path forward that supports and empowers the best of what it is to invest in cancer research.

January 31, 2025

Vol.51 No.04

By W. Kimryn Rathmell

Guest Editorial

Foundations acquire a critical new role as federal funding for cancer research falters

The fight against cancer is complex. It’s global. And it’s indisputably expensive.

January 31, 2025

Vol.51 No.04

By Ryan Schoenfeld and Raymond N. DuBois

Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies.

January 31, 2025

Vol.51 No.04

By Ze’ev Ronai

NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century

Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to a modeling study led by researchers at NCI.

January 31, 2025

Vol.51 No.04

By Yiqing Wang and Jacquelyn Cobb